Advanced NSCLC in Focus: Collaborative Management of EGFR Mutation and ALK Rearrangement Disease
Danny Nguyen, MD; Katherine Cunha, MSN, FNP-C; Michelle Munroe, APRN; and Jun Zhang, MD, PhD, discuss how to optimize treatment selection and manage adverse events in patients with advanced non–small cell lung cancer (NSCLC) with EGFR mutations and ALK rearrangements, emphasizing collaborative care strategies, patient education, and proactive adverse effect management to maintain treatment adherence and quality of life.
EP. 1: Clinical Case: EGFR-Mutant (Exon 19 del) Advanced NSCLC
June 25th 2025Panelists discuss how a 46-year-old graphic designer with stage IV EGFR-mutant non–small cell lung cancer and brain metastases was successfully treated with amivantamab plus lazertinib after weighing multiple frontline treatment options.
EP. 2: The Treatment Landscape For Advanced EGFR-Mutant NSCLC
June 25th 2025Panelists discuss how the treatment landscape for EGFR-mutant non–small cell lung cancer has evolved to include 3 viable frontline options (osimertinib alone, osimertinib plus chemotherapy, and amivantamab plus lazertinib), with treatment selection based on patient characteristics, preferences, and physician judgment rather than a strict algorithmic approach.
EP. 3: Emerging Insights From MARIPOSA: OS Updates From Amivantamab/Lazertinib in Advanced NSCLC
July 2nd 2025Panelists discuss how the MARIPOSA study demonstrated significant progression-free survival and overall survival (OS) benefits with amivantamab plus lazertinib vs osimertinib monotherapy, with mature overall survival data showing a 25% improvement in survival outcomes.
EP. 4: Navigating CNS Disease in EGFR-Mutant NSCLC
July 2nd 2025Panelists discuss how both amivantamab plus lazertinib and osimertinib-based regimens show good central nervous system activity for patients with baseline brain metastases, with treatment choice influenced more by patient-specific factors like bleeding risk and anticoagulation contraindications than by CNS efficacy differences.
EP. 5: From Trial to Practice: Integrating Amivantamab/Lazertinib in Advanced NSCLC
July 11th 2025Panelists discuss how real-world experience with amivantamab plus lazertinib has shown remarkable responses consistent with trial data, including effectiveness in challenging cases like leptomeningeal disease, with manageable adverse effects when proper prophylactic measures and patient education are implemented.
EP. 6: Patient Education and IRR Prophylaxis in Practice With Amivantamab/Lazertinib
July 11th 2025Panelists discuss how comprehensive patient education about expected adverse effects, combined with prophylactic measures including dexamethasone premedication and dermatologic support, helps patients successfully tolerate amivantamab plus lazertinib therapy while maintaining treatment adherence.
